(Q40679797)

22 September 2017

title

A placebo-controlled trial of gabapentin in spinal muscular atrophy (English)

1 reference

22 September 2017

0 references

0 references

spinal muscular atrophy

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

R G Miller

1

1 reference

22 September 2017

D H Moore

2

1 reference

22 September 2017

V Dronsky

3

1 reference

22 September 2017

W Bradley

4

1 reference

22 September 2017

R Barohn

5

1 reference

22 September 2017

W Bryan

6

1 reference

22 September 2017

T W Prior

7

1 reference

22 September 2017

D F Gelinas

8

1 reference

22 September 2017

S Iannaccone

9

1 reference

22 September 2017

J Kissel

10

1 reference

22 September 2017

R Leshner

11

1 reference

22 September 2017

J Mendell

12

1 reference

22 September 2017

M Mendoza

13

1 reference

22 September 2017

B Russman

14

1 reference

22 September 2017

F Samaha

15

1 reference

22 September 2017

S Smith

16

1 reference

22 September 2017

SMA Study Group

17

1 reference

22 September 2017

publication date

1 October 2001

1 reference

Journal of the Neurological Sciences

22 September 2017

published in

1 reference

22 September 2017

volume

191

1 reference

22 September 2017

issue

1-2

1 reference

22 September 2017

page(s)

127-131

1 reference

22 September 2017

cites work

Spinal muscular atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Identification and characterization of a spinal muscular atrophy-determining gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

SMN oligomerization defect correlates with spinal muscular atrophy severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Possible strategies for treatment of SMA patients: a neurobiologist's view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Prospective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

International SMA consortium meeting. (26-28 June 1992, Bonn, Germany)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900632-3

10.1016/S0022-510X(01)00632-3

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference